S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.15 CNY -0.1%
Market Cap: 34.7B CNY
Have any thoughts about
Shenzhen Salubris Pharmaceuticals Co Ltd?
Write Note

Shenzhen Salubris Pharmaceuticals Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Salubris Pharmaceuticals Co Ltd
Other Current Liabilities Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Other Current Liabilities
ÂĄ448.1m
CAGR 3-Years
14%
CAGR 5-Years
10%
CAGR 10-Years
-1%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Liabilities
ÂĄ530.5m
CAGR 3-Years
-8%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Liabilities
ÂĄ299.9m
CAGR 3-Years
-2%
CAGR 5-Years
-10%
CAGR 10-Years
11%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
19%
CAGR 5-Years
26%
CAGR 10-Years
25%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Liabilities
ÂĄ3.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
13%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Liabilities
ÂĄ101.9m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Other Current Liabilities?
Other Current Liabilities
448.1m CNY

Based on the financial report for Jun 30, 2024, Shenzhen Salubris Pharmaceuticals Co Ltd's Other Current Liabilities amounts to 448.1m CNY.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-1%

Over the last year, the Other Current Liabilities growth was 188%. The average annual Other Current Liabilities growth rates for Shenzhen Salubris Pharmaceuticals Co Ltd have been 14% over the past three years , 10% over the past five years , and -1% over the past ten years .

Back to Top